Biolinerx Stock Analysis
| BLRX Stock | USD 3.10 0.14 4.73% |
IPO Date 25th of July 2011 | 200 Day MA 3.7354 | 50 Day MA 3.7586 | Beta 0.578 |
BioLineRx holds a debt-to-equity ratio of 0.046. At this time, BioLineRx's Total Debt To Capitalization is fairly stable compared to the past year. Debt Equity Ratio is likely to rise to 1.06 in 2026, whereas Long Term Debt Total is likely to drop slightly above 6 M in 2026. With a high degree of financial leverage come high-interest payments, which usually reduce BioLineRx's Earnings Per Share (EPS).
Asset vs Debt
Equity vs Debt
BioLineRx's liquidity is one of the most fundamental aspects of both its future profitability and its ability to meet different types of ongoing financial obligations. BioLineRx's cash, liquid assets, total liabilities, and shareholder equity can be utilized to evaluate how much leverage the Company is using to sustain its current operations. For traders, higher-leverage indicators usually imply a higher risk to shareholders. In addition, it helps BioLineRx Stock's retail investors understand whether an upcoming fall or rise in the market will negatively affect BioLineRx's stakeholders.
For most companies, including BioLineRx, marketable securities, inventories, and receivables are the most common assets that could be converted to cash. However, for BioLineRx, the most critical issue when managing liquidity is ensuring that current assets are properly aligned with current liabilities. If they are not, BioLineRx's management will need to obtain alternative financing to ensure there are always enough cash equivalents on the balance sheet to meet obligations.
Price Book 0.6906 | Enterprise Value Ebitda 1.1052 | Price Sales 1.1426 | Shares Float 2.5 B | Wall Street Target Price 26 |
Given that BioLineRx's debt-to-equity ratio measures a Company's obligations relative to the value of its net assets, it is usually used by traders to estimate the extent to which BioLineRx is acquiring new debt as a mechanism of leveraging its assets. A high debt-to-equity ratio is generally associated with increased risk, implying that it has been aggressive in financing its growth with debt. Another way to look at debt-to-equity ratios is to compare the overall debt load of BioLineRx to its assets or equity, showing how much of the company assets belong to shareholders vs. creditors. If shareholders own more assets, BioLineRx is said to be less leveraged. If creditors hold a majority of BioLineRx's assets, the Company is said to be highly leveraged.
At this time, BioLineRx's Common Stock Shares Outstanding is fairly stable compared to the past year. Liabilities And Stockholders Equity is likely to rise to about 51.4 M in 2026, whereas Total Stockholder Equity is likely to drop slightly above 14.7 M in 2026. . At this time, BioLineRx's Price Book Value Ratio is fairly stable compared to the past year. Price To Book Ratio is likely to rise to 1.81 in 2026, whereas Price To Sales Ratio is likely to drop 0.81 in 2026. BioLineRx is overvalued with Real Value of 2.66 and Target Price of 26.0. The main objective of BioLineRx stock analysis is to determine its intrinsic value, which is an estimate of what BioLineRx is worth, separate from its market price. There are two main types of BioLineRx's stock analysis: fundamental analysis and technical analysis.
The BioLineRx stock is traded in the USA on NASDAQ Exchange, with the market opening at 09:30:00 and closing at 16:00:00 every Mon,Tue,Wed,Thu,Fri except for officially observed holidays in the USA. BioLineRx is usually not traded on Labour Day, Thanksgiving Day, Christmas Day, New Year 's Day, Dr . Martin Luther King Jr 's Birthday, Washington 's Birthday, Good Friday, Memorial Day, Juneteenth Holiday, Independence Day ( substitute day ), Independence Day. BioLineRx Stock trading window is adjusted to America/New York timezone.
BioLineRx | Build AI portfolio with BioLineRx Stock |
BioLineRx Stock Analysis Notes
The company has price-to-book (P/B) ratio of 0.69. Some equities with similar Price to Book (P/B) outperform the market in the long run. BioLineRx has Price/Earnings To Growth (PEG) ratio of 0.2. The entity recorded a loss per share of 6.0. The firm last dividend was issued on the 15th of July 2019. BioLineRx had 1:40 split on the 30th of January 2025. BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people. For more info on BioLineRx please contact the company at 972 8 642 9100 or go to https://www.biolinerx.com.BioLineRx Investment Alerts
| BioLineRx generated a negative expected return over the last 90 days | |
| BioLineRx has high historical volatility and very poor performance | |
| BioLineRx has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 28.94 M. Net Loss for the year was (9.22 M) with profit before overhead, payroll, taxes, and interest of 10.23 M. | |
| BioLineRx currently holds about 43.15 M in cash with (43.87 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9. | |
| Latest headline from news.google.com: Growth Review Why BioLineRx Ltd Depositary Receipt stock attracts high net worth investors - July 2025 Spike Watch Daily Entry Point Trade Alerts - moha.gov.vn |
BioLineRx Largest EPS Surprises
Earnings surprises can significantly impact BioLineRx's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2023-05-25 | 2023-03-31 | -0.17 | -0.15 | 0.02 | 11 | ||
2022-09-30 | 2022-06-30 | -0.11 | -0.15 | -0.04 | 36 | ||
2022-03-16 | 2021-12-31 | -0.14 | -0.1 | 0.04 | 28 |
BioLineRx Environmental, Social, and Governance (ESG) Scores
BioLineRx's ESG score is a quantitative measure that evaluates BioLineRx's performance and commitment regarding environmental, social, and governance (ESG) factors. These scores are becoming increasingly crucial in investment decision-making processes, providing insights into non-financial aspects of BioLineRx's operations that may have significant financial implications and affect BioLineRx's stock price as well as guide investors towards more socially responsible investments.
BioLineRx Stock Institutional Investors
| Shares | Bank Of America Corp | 2025-06-30 | 2.0 | Advisor Group Holdings, Inc. | 2025-06-30 | 1.0 | Captrust Financial Advisors | 2025-03-31 | 0.0 | Watts Gwilliam And Company, Llc | 2025-03-31 | 0.0 | Geneos Wealth Management Inc | 2025-03-31 | 0.0 | Bnp Paribas Arbitrage, Sa | 2025-06-30 | 0.0 | Values First Advisors Inc | 2025-03-31 | 0.0 | Hibernia Wealth Partners Llc | 2025-03-31 | 0.0 | Weaver Consulting Group | 2025-03-31 | 0.0 | Citadel Advisors Llc | 2025-06-30 | 15 K | Simplex Trading, Llc | 2025-06-30 | 14.1 K |
BioLineRx Market Capitalization
The company currently falls under 'Micro-Cap' category with a current market capitalization of 15.18 M.BioLineRx Profitablity
The company has Profit Margin (PM) of (0.45) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (7.58) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $7.58.| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.37) | (0.39) | |
| Return On Capital Employed | (1.00) | (1.05) | |
| Return On Assets | (0.21) | (0.22) | |
| Return On Equity | (0.79) | (0.83) |
Management Efficiency
BioLineRx has return on total asset (ROA) of (0.1536) % which means that it has lost $0.1536 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4594) %, meaning that it created substantial loss on money invested by shareholders. BioLineRx's management efficiency ratios could be used to measure how well BioLineRx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.39 in 2026. Return On Capital Employed is likely to drop to -1.05 in 2026. At this time, BioLineRx's Total Assets are fairly stable compared to the past year. Total Current Assets is likely to rise to about 39.6 M in 2026, whereas Non Current Assets Total are likely to drop slightly above 11.8 M in 2026.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 0.01 | 0.01 | |
| Enterprise Value Over EBITDA | 5.97 | 6.27 | |
| Price Book Value Ratio | 1.43 | 1.81 | |
| Enterprise Value Multiple | 5.97 | 6.27 | |
| Price Fair Value | 1.43 | 1.81 | |
| Enterprise Value | 23.4 M | 41.9 M |
The strategic initiatives led by BioLineRx's management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Technical Drivers
As of the 27th of January, BioLineRx shows the Standard Deviation of 3.11, mean deviation of 2.51, and Risk Adjusted Performance of (0.05). BioLineRx technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.BioLineRx Price Movement Analysis
The output start index for this execution was twenty-three with a total number of output elements of thirty-eight. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. BioLineRx middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for BioLineRx. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
BioLineRx Predictive Daily Indicators
BioLineRx intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of BioLineRx stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
BioLineRx Forecast Models
BioLineRx's time-series forecasting models are one of many BioLineRx's stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary BioLineRx's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.BioLineRx Debt to Cash Allocation
As BioLineRx follows its natural business cycle, the capital allocation decisions will not magically go away. BioLineRx's decision-makers have to determine if most of the cash flows will be poured back into or reinvested in the business, reserved for other projects beyond operational needs, or paid back to stakeholders and investors.
BioLineRx currently holds 15.04 M in liabilities with Debt to Equity (D/E) ratio of 0.05, which may suggest the company is not taking enough advantage from borrowing. BioLineRx has a current ratio of 4.49, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about BioLineRx's use of debt, we should always consider it together with its cash and equity.BioLineRx Total Assets Over Time
BioLineRx Assets Financed by Debt
The debt-to-assets ratio shows the degree to which BioLineRx uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.BioLineRx Debt Ratio | 37.0 |
BioLineRx Net Debt
Net Debt |
|
About BioLineRx Stock Analysis
Stock analysis is the technique used by a trader or investor to examine and evaluate how BioLineRx prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling BioLineRx shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as BioLineRx. By using and applying BioLineRx Stock analysis, traders can create a robust methodology for identifying BioLineRx entry and exit points for their positions.
| Last Reported | Projected for Next Year | ||
| Pretax Profit Margin | (0.37) | (0.38) | |
| Operating Profit Margin | (0.81) | (0.85) | |
| Net Loss | (0.37) | (0.38) | |
| Gross Profit Margin | 0.78 | 0.62 |
Current BioLineRx Analysis - Recommendations
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. BioLineRx analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. BioLineRx analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
| Target Price | Advice | # of Analysts | |
| 26.0 | Strong Buy | 2 | Odds |
Most BioLineRx analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand BioLineRx stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of BioLineRx, talking to its executives and customers, or listening to BioLineRx conference calls.
BioLineRx Stock Analysis Indicators
BioLineRx stock analysis indicators help investors evaluate how BioLineRx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading BioLineRx shares will generate the highest return on investment. By understating and applying BioLineRx stock analysis, traders can identify BioLineRx position entry and exit signals to maximize returns.
| Begin Period Cash Flow | 4.3 M | |
| Long Term Debt | 9 M | |
| Common Stock Shares Outstanding | 79.9 M | |
| Total Stockholder Equity | 13.5 M | |
| Total Cashflows From Investing Activities | 29.4 M | |
| Property Plant And Equipment Net | 1.4 M | |
| Cash And Short Term Investments | 19.6 M | |
| Cash | 10.4 M | |
| Accounts Payable | 5.6 M | |
| Net Debt | 4.6 M | |
| 50 Day M A | 3.7586 | |
| Total Current Liabilities | 15.4 M | |
| Other Operating Expenses | 49.3 M | |
| Non Current Assets Total | 11.8 M | |
| Forward Price Earnings | 93.4579 | |
| Stock Based Compensation | 1.1 M |
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.